F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-...
New strategic collaboration to develop and commercialise five bispecific immuno-oncology antibodies, including F-star’s lead asset FS118 F-star to receive up to €115 million over the first two years Merck has option to acquire the programmes, with …